CD20 Archives - Medical Conferences

Ofatumumab: good initial adherence and treatment satisfaction

Presented By

Dr Anneke van der Walt, Monash University, Australia

Trial

EAFToS

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:24

Higher-dosed ocrelizumab associated with less disability accrual

Presented By

Dr Robert Bermel, Cleveland Clinic, OH, USA

Trial

Phase 3, OPERA

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:21

Ocrelizumab significantly reduces new/enlarging cortical lesions

Presented By

Prof. Michael Dwyer, University at Buffalo, NY, USA

Trial

Phase 3, ORATORIO

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:19

Safety of 30-minute ublituximab infusions confirmed

Presented By

Dr John Foley, Rocky Mountain Multiple Sclerosis Center, UT, USA

Trial

ENHANCE

Conference

ACTRIMS 2025

Type

News article

28 March 2025 11:12

B cell-tailored dosing of ocrelizumab shows good results

Presented By

Ms Laura Hogenboom, Amsterdam University Medical Center, the Netherlands

Trial

BLOOMS

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:28

EPCORE CLL-1: Promising data for epcoritamab in high-risk Richter’s transformation

Presented By

Prof. Arnon Kater, University of Amsterdam, the Netherlands

Trial

Phase 1/2, EPCORE CLL-1

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:27

Clinically meaningful outcomes for mosunetuzumab across follicular lymphoma subgroups

Presented By

Dr Sarit Assouline, Jewish General Hospital, Canada

Trial

Phase 1/2

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:26

Primary phase 2 efficacy and safety results of M-Pola in relapsed/refractory LBCL

Presented By

Dr Elizabeth Budde, City of Hope National Medical Center, CA, USA

Trial

Phase 1/2

Conference

ASH 2023

Type

Peer-reviewed article

7 February 2024 14:59

New safety data of anti-CD20 mAbs around pregnancy

Presented By

Dr Carolin Schwake, Ruhr-University Bochum, Germany

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 10:24

Chronic active MS lesions respond poorly to anti-CD20 antibodies

Presented By

Dr Pietro Maggi, Saint-Luc University Hospital, Belgium

Conference

ECTRIMS 2022

Type

Peer-reviewed article

19 December 2022 19:06

Updated EAN-ECTRIMS guideline on pharmacological MS treatment

Presented By

Prof. Maria Pia Amato, University of Florence, Italy

Conference

EAN 2022

Type

Peer-reviewed article

22 August 2022 15:31

Triple-therapy improves PFS in fit, previously untreated CLL

Presented By

Prof. Barbara Eichhorst, University Hospital Cologne, Germany

Trial

Phase 3, GAIA/CLL13

Conference

EHA 2022

Type

News article

1 July 2022 11:43

Immunotherapy in MS does not influence COVID-19 severity and mortality

Presented By

Dr Gabriel Bsteh, Medical University of Vienna, Austria

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 10:45

Positive results from ublituximab versus teriflunomide

Trial

Phase 3, ULTIMATE I, ULTIMATE II

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:35

ELEVATE-TN: Long-term efficacy in chronic lymphocytic leukemia

Presented By

Dr. John Byrd, Ohio State University College of Medicine, USA

Trial

Phase 3, ELEVATE-TN

Journal

Physician's Weekly

Conference

ASCO 2021

6 August 2021 11:20

No association between Ig levels and infection in ofatumumab-treated patients with relapsing MS

Presented By

Prof. Heinz Wiendl , University of Muenster, Germany

Trial

Phase 3, ASCLEPIOS

Conference

ECF 2020

Type

News article

16 December 2020 16:12

Anti-CD20 DMTs associated with worse COVID-19 outcomes

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:09

No new safety signals in ofatumumab open-label data

Trial

ALITHIOS, ASCLEPIOS I, ASCLEPIOS II, APLIOS

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:57

Low-dose rituximab as effective as high-dose, but safer

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:57

Promising first-in-human trial of epcoritamab in B-NHL

Presented By

Dr Martin Hutchings, Copenhagen University Hospital, Denmark

Trial

Phase 1/2, GEN3013

Conference

EHA 2020

Type

Peer-reviewed article

9 September 2020 12:30

Off-the-shelf natural killer cells

Presented By

Dr Jode Goodridge, Fate Therapeutics, USA

Conference

ASH 2019

Type

Peer-reviewed article

5 March 2020 09:38